Netherlands Pharmaceutical Market Introduction and Overview
According to SPER Market Research, the Netherlands Pharmaceutical Market is estimated to reach USD XX billion by 2033 with a CAGR of 6.11%.
The report includes an in-depth analysis of the Netherlands Pharmaceutical Market, including market size and trends, product mix, applications, and supplier analysis. A pharmaceutical is any medicine that is prescribed or utilised for therapeutic purposes. Pharmaceuticals are goods with drugs in them in precise quantities that can be administered to patients. People are become more and more conscious about their health and lives. This serves as the market's catalyst.
- July 2022: A warning letter was sent by the US FDA to a Dutch manufacturer of APIs, or active pharmaceutical ingredients. It was given notice to implement stronger procedures for cleaning equipment and greater safety measures to avoid cross-contamination.
- May 2022: The Netherlands-based pharmaceutical business Centrient Pharmaceuticals has declared that it has fully complied with the anti-microbial resistance industry alliance's strict Predicted No Effect Concentration (PNEC) discharge targets for the clean production of its whole line of oral antibiotic products.
Market Opportunities and Challenges
The nation is ideally situated for biopharmaceutical operations, with top-notch research institutes, a highly educated workforce, a first-rate healthcare system, and a government that supports innovation. The rise in healthcare and medical spending in recent years is indicative of the great potential for new drug research, infrastructure development, and entry/expansion opportunities. Pharmaceutical firms' profitability is predicted to suffer as a result of the government's simultaneous measures to reduce the cost of pharmaceutical items. It is anticipated that the Netherlands would shortly bargain with pharmaceutical corporations to reduce the prices of drugs. As a result, growth in the market is predicted throughout the forecast period due to the aforementioned factors.
The pharmaceutical market faces challenges such as a high failure rate and escalating development costs for new products, impeding overall growth. A significant hurdle is the scarcity of a skilled workforce, particularly for drugs requiring specialized expertise, confined to specific research organizations and medical equipment sectors. Fluctuating raw material prices further limit market expansion. Moreover, a widening talent gap is evident as the pharmaceutical workforce struggles to align skills with the demands of modern biopharma production, particularly in areas like automation, computer science, and process modelling. This unaddressed skills gap poses a potential threat to innovation within the industry.
Market Competitive Landscape
There are multiple prominent firms in the somewhat fragmented pharmaceutical sector. Currently, a small number of the main competitors control the majority of the market share. Prominent entities are actively pursuing acquisitions and joint partnerships with other businesses in an effort to strengthen their market positions inside the nation. The major players in the Netherlands Pharmaceutical market include: Abbott Laboratories, AbbVie Inc., Amgen Inc., Astellas Pharma, AstraZeneca PLC, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By ATC/Therapeutic Class, By Mode of Dispensing
|
| Regions covered | East Netherlands, North Netherlands, South Netherlands, West Netherlands
|
| Companies Covered | Abbott Laboratories, AbbVie Inc., Amgen Inc., Astellas Pharma, AstraZeneca PLC, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Others
|
COVID-19 Impact on Netherlands Pharmaceutical Market
Early on in the COVID-19 pandemic, a number of lockdown laws were implemented, which had a big effect on the market. As per a January 2021 PubMed Central publication, a cross-sectional study was conducted and the results indicated a significant effect of the COVID-19 pandemic on the logistic procedures and services provided by Dutch pharmacies. Pharmaceutical sales decreased as a result of the decline in these services. As a result, the market was originally significantly impacted by the COVID-19 pandemic. Nonetheless, the market under investigation is anticipated to increase steadily following the pandemic during the study's projected period.
Key Target Audience
- Government Health Departments
- Healthcare Professionals
- Patients and Patient Advocacy Groups
- Pharmaceutical Companies
- Pharmacy Chains and Retailers
- Research and Development Institutes
- Others
Our in-depth analysis of the Netherlands Pharmaceutical Market includes the following segments:
|
By ATC/Therapeutic Class
|
Alimentary Tract and Metabolisma
Antiinfectives for Systemic Use
Antineoplastic and Immunomodulating Agents
Antiparasitic Products, Insecticides, and Repellents
Blood and Blood-forming Organs
Cardiovascular System
Dermatological Drugs
|
|
By Mode of Dispensing
|
OTC
Prescription
|
|
By Region
|
East Netherlands
North Netherlands
South Netherlands
West Netherlands
|
Key Topics Covered in the Report
- Netherlands Pharmaceutical Market Size (FY’2023-FY’2033)
- Overview of Netherlands Pharmaceutical Market
- Segmentation of Netherlands Pharmaceutical Market By ATC/Therapeutic Class (Alimentary Tract and Metabolisma, Antiinfectives for Systemic Use, Antineoplastic and Immunomodulating Agents, Antiparasitic Products, Insecticides, and Repellents, Blood and Blood-forming Organs, Cardiovascular System, Dermatological Drugs, Genitourinary System and Reproductive Hormones, Musculoskeletal System, Nervous System, Respiratory System, Sensory Organs, Systemic Hormonal Preparations, Excluding Reproductive Hormones and Insulins, Various ATC Structures)
- Segmentation of Netherlands Pharmaceutical Market By Mode of Dispensing (OTC, Prescription)
- Statistical Snap of Netherlands Pharmaceutical Market
- Expansion Analysis of Netherlands Pharmaceutical Market
- Problems and Obstacles in Netherlands Pharmaceutical Market
- Competitive Landscape in the Netherlands Pharmaceutical Market
- Impact of COVID-19 and Demonetization on Netherlands Pharmaceutical Market
- Details on Current Investment in Netherlands Pharmaceutical Market
- Competitive Analysis of Netherlands Pharmaceutical Market
- Prominent Players in the Netherlands Pharmaceutical Market
- SWOT Analysis of Netherlands Pharmaceutical Market
- Netherlands Pharmaceutical Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Netherlands Pharmaceutical Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Netherlands Pharmaceutical Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Netherlands Pharmaceutical Market
7. Netherlands Pharmaceutical Market, By ATC/Therapeutic Class (USD Million)
7.1. Netherlands Pharmaceutical Market Value Share and Forecast, By ATC/Therapeutic Class, 2023-2033
7.2. Alimentary Tract and Metabolisma
7.3. Antiinfectives for Systemic Use
7.4. Antineoplastic and Immunomodulating Agents
7.5. Antiparasitic Products, Insecticides, and Repellents
7.6. Blood and Blood-forming Organs
7.7. Cardiovascular System
7.8. Dermatological Drugs
7.9. Genitourinary System and Reproductive Hormones
7.10. Musculoskeletal System
7.11. Nervous System
7.12. Respiratory System
7.13. Sensory Organs
7.14. Systemic Hormonal Preparations, Excluding Reproductive Hormones and Insulins
7.15. Various ATC Structures
8. Netherlands Pharmaceutical Market, By Mode of Dispensing (USD Million)
8.1. Netherlands Pharmaceutical Market Value Share and Forecast, By Mode of Dispensing, 2023-2033
8.2. OTC
8.3. Prescription
9. Netherlands Pharmaceutical Market Forecast, 2019-2033 (USD Million)
9.1. Netherlands Pharmaceutical Market Size and Market Share
10. Netherlands Pharmaceutical Market, By ATC/Therapeutic Class, 2019-2033 (USD Million)
10.1. Netherlands Pharmaceutical Market Size and Market Share By ATC/Therapeutic Class (2019-2026)
10.2. Netherlands Pharmaceutical Market Size and Market Share By ATC/Therapeutic Class (2027-2033)
11. Netherlands Pharmaceutical Market, By Mode of Dispensing, 2019-2033 (USD Million)
11.1. Netherlands Pharmaceutical Market Size and Market Share By Mode of Dispensing (2019-2026)
11.2. Netherlands Pharmaceutical Market Size and Market Share By Mode of Dispensing (2027-2033)
12. Netherlands Pharmaceutical Market, By Region, 2019-2033 (USD Million)
12.1. Netherlands Pharmaceutical Market Size and Market Share By Region (2019-2026)
12.2. Netherlands Pharmaceutical Market Size and Market Share By Region (2027-2033)
12.3. East Netherlands
12.4. North Netherlands
12.5. South Netherlands
12.6. West Netherlands
13. Company Profile
13.1. Abbott Laboratories
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. AbbVie Inc.
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Amgen Inc.
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. Astellas Pharma
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. AstraZeneca PLC
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. F. Hoffmann-La Roche AG
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. Johnson & Johnson
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Merck & Co.
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Novartis AG
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Pfizer Inc.
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Others
14. List of Abbreviations
15. Reference Links
16. Conclusion
17. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
